Arzneimittel mit dem Wirkstoff Rasagilin (ATC: N04BD02)

TENDER DESCRIPTION

Conclusion of non-exclusive rebate agreements pursuant to § 130a para. 8 SGB V for finished medicinal products containing the active substance Rasagiline (ATC: N04BD02) with the possibility to conclude at any time within the framework of a so-called "open-house model." A contract will be concluded with every pharmaceutical company that meets the participation requirements. Exclusivity is not given. Accession or contract conclusion can occur at any time and under the same conditions. Individual contract negotiations will not be conducted. The earliest contract start date is 01.10.2026. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.09.2028 regardless of the contract start date. Should AOK Sachsen-Anhalt, during the contract period and pursuant to the relevant procurement law provisions, tender exclusive contracts for the active substances, the contracts concluded under this publication will be terminated in accordance with the contractual provisions. This publication does not constitute the award of a public contract within the meaning of § 103 GWB or procurement law. To ensure the greatest possible degree of transparency for the intended…

TENDER BRIEF

TENDER DOCUMENTS